Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | GGPS1 | O95749 | 10/20 | 0.36 |
| ▸ | CCR2 | P41597 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17106359 | 0.80 | MAPK1 (0.41) | MAPK1GGPS1CCR2L3MBTL1MEN1 | |
| SCHEMBL1114811 | 0.78 | MAPK1 (0.40) | MAPK1GGPS1CCR2L3MBTL1MEN1 | |
| Phosphonic Acid SCHEMBL11463638 | 0.77 | MAPK1 (0.37) | MAPK1GGPS1CCR2L3MBTL1MEN1 | |
| SCHEMBL2440426 | 0.76 | MAPK1 (0.39) | MAPK1GGPS1CCR2L3MBTL1MEN1 | |
| SCHEMBL2438894 | 0.74 | MAPK1 (0.38) | MAPK1GGPS1CCR2L3MBTL1MEN1 | |
| SCHEMBL1114546 | 0.73 | — | — | |
| SCHEMBL1114586 | 0.73 | MAPK1 (0.41) | MAPK1GGPS1CCR2L3MBTL1MEN1 | |
| SCHEMBL81453 | 0.73 | MAPK1 (0.37) | MAPK1GGPS1CCR2L3MBTL1MEN1 | |
| SCHEMBL2441710 | 0.70 | MAPK1 (0.41) | MAPK1GGPS1CCR2L3MBTL1MEN1 | |
| SCHEMBL10655712 | 0.70 | CYP4F2 (0.46) | MAPK1L3MBTL1MEN1ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2279741-A2 | Caprolactams and their use as anti-inflammatory agents | Cambridge Enterprise Ltd. (GB) | 2011-02-02 | — | — | EP | claimed |
| US-20080227724-A1 | 3-(alkanoyl or alkenoyl)amino-caprolactams; autoimmune diseases, asthma, osteoporosis, transplant rejection, psoriasis, Alzheimer's Disease, Multiple sclerosis, ALS; antitumor, antiarthritic, antifibrotic, and antiscarring agents | CAMBRIDGE UNIVERSITY TECHNICAL SERVICES LIMITED (GB) | 2008-09-18 | — | — | US | claimed |
| EP-1691814-A2 | ANTI-INFLAMMATORY AGENTS | CAMBRIDGE UNIVERSITY TECHNICAL SERVICES LIMITED (GB) | 2006-08-23 | — | — | EP | claimed |
| WO-2005053702-A2 | ANTI-INFLAMMATORY AGENTS | CAMBRIDGE UNIVERSITY TECHNICAL SERVICES LIMITED (GB) | 2005-06-16 | — | — | WO | claimed |
| EP-1691814-B9 | ANTI-INFLAMMATORY AGENTS | CAMBRIDGE ENTPR LTD (GB) | 2013-02-20 | — | — | EP | disclosed |
| EP-1691814-B1 | ANTI-INFLAMMATORY AGENTS | CAMBRIDGE ENTPR LTD (GB) | 2012-07-25 | — | — | EP | disclosed |
| EP-2279741-A2 | Caprolactams and their use as anti-inflammatory agents | Cambridge Enterprise Ltd. (GB) | 2011-02-02 | — | — | EP | disclosed |
| US-20080227724-A1 | 3-(alkanoyl or alkenoyl)amino-caprolactams; autoimmune diseases, asthma, osteoporosis, transplant rejection, psoriasis, Alzheimer's Disease, Multiple sclerosis, ALS; antitumor, antiarthritic, antifibrotic, and antiscarring agents | CAMBRIDGE UNIVERSITY TECHNICAL SERVICES LIMITED (GB) | 2008-09-18 | — | — | US | disclosed |
| EP-1691814-A2 | ANTI-INFLAMMATORY AGENTS | CAMBRIDGE UNIVERSITY TECHNICAL SERVICES LIMITED (GB) | 2006-08-23 | — | — | EP | disclosed |
| WO-2005053702-A2 | ANTI-INFLAMMATORY AGENTS | CAMBRIDGE UNIVERSITY TECHNICAL SERVICES LIMITED (GB) | 2005-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227724-A1 | 3-(alkanoyl or alkenoyl)amino-caprolactams; autoimmune diseases, asthma, osteoporosis, transplant rejection, psoriasis, Alzheimer's Disease, Multiple sclerosis, ALS; antitumor, antiarthritic, antifibrotic, and antiscarring agents | SMURF1, SMURF2, PSEN1 | MAPK1 3301/4885GGPS1 1345/4885CCR2 1075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.